DFTX insider trading
HealthcareDefinium Therapeutics, Inc.: insider trade history from SEC Form 4 filings.
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Company website: definiumtx.com
DFTX insider activity at a glance
FilingIQ tracks 43 insider transactions for DFTX in filings since Feb 5, 2026. The most recent transaction is dated Sep 25, 2026.
Across the full history, 0 open-market purchases
and 14 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
Latest DFTX Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Top insiders trading DFTX
13F funds holding DFTX
Frequently asked
- How many insider trades does FilingIQ track for DFTX?
- FilingIQ tracks 43 Form 4 insider transactions for DFTX (Definium Therapeutics, Inc.), covering filings from Feb 5, 2026 onwards. 19 of those are dated within the last 90 days.
- Are DFTX insiders net buyers or net sellers?
- Across the full Form 4 history for DFTX, 0 transactions (0%) were open-market purchases and 14 (33%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does DFTX insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is DFTX in?
- Definium Therapeutics, Inc. (DFTX) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $1.64B.
Methodology & sources
Every DFTX insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.